U.S. Cell Culture Media Market Challenges, Import Export Consumption, Demand and Forecast 2030

U.S. Cell Culture Media Market Summary

The U.S. cell culture media market was valued at USD 1.46 billion in 2023 and is projected to grow at a strong compound annual growth rate (CAGR) of 10.95% from 2024 to 2030. This anticipated growth is primarily driven by the continuously increasing use of cell culture technology across various research and clinical applications. Additionally, growing awareness surrounding the potential of stem cells is significantly contributing to the rising utilization of cell and gene therapy, further strengthening demand for high-performance culture media tailored to advanced biomedical research and therapeutic development.

In 2023, the U.S. accounted for 31% of the global cell culture media market, reflecting its leading position in biotechnology and life sciences. One of the major growth enablers in the country is the presence of a highly developed research and development (R&D) infrastructure, supported by an adaptable and supportive regulatory environment. This ecosystem has evolved in parallel with the rapid advancements in genetic engineering, stem cell research, and therapeutic technologies. The regulatory framework is maintained by three key federal agencies—Animal and Plant Health Inspection Service (APHIS), U.S. Environmental Protection Agency (EPA), and the Food and Drug Administration (FDA) under the U.S. Department of Health and Human Services—which collectively ensure the safe development and use of genetically engineered organisms and advanced biological processes.

Key Market Trends & Insights

• The serum-free media segment recorded the highest revenue share of 37.20% in 2023. The growing preference for serum-free formulations stems from their expanding application scope and the significant advantages they offer in terms of product consistency, reduced contamination risks, and improved downstream processing. Serum-free media provide more precise evaluation of cellular behavior and functions, making them ideal for applications that require controlled experimental conditions and clearer interpretation of cellular responses. Additionally, they facilitate better identification of cellular mediators, improving the quality and accuracy of research outcomes.
• The biopharmaceutical production segment led the market with the highest revenue share of 43.00% in 2023. The rising need for reliable, reproducible, and well-defined media to support the expanding scale of biologics manufacturing is a major growth driver in this segment. The demand is further amplified by the requirement to minimize contamination in downstream processes, thus ensuring product safety and efficacy. This trend is particularly evident in the production of monoclonal antibodies, recombinant proteins, and cell-based therapeutics, where high-quality media formulations are essential for maintaining consistent batch-to-batch performance.
• In terms of media type, the liquid media segment held the dominant share of 63.2% in 2023. This segment’s strong position is attributed to the increasing number of biologics and biosimilar producers that rely heavily on liquid media for efficient cell culture processes. Liquid media are particularly preferred due to their ability to limit the proliferation of mycobacteria and other contaminants while maintaining optimal cell growth conditions. The convenience and cost-effectiveness of liquid formulations in large-scale bioproduction also contribute to their widespread adoption in both research and industrial applications.
• The pharmaceutical and biotechnology end-use segment accounted for the largest revenue share of 34.91% in 2023. The steady introduction of biosimilars and novel therapeutic alternatives is propelling demand in this segment. An increasing number of clinical trials targeting chronic and life-threatening diseases has further intensified the use of specialized cell culture media by pharmaceutical and biotechnology firms. These organizations are investing significantly in R&D to develop innovative therapies, thereby driving a sustained need for media that supports both exploratory research and commercial-scale manufacturing of therapeutic solutions.

Order a free sample PDF of the U.S. Cell Culture Media Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 1.46 billion
• 2030 Projected Market Size: USD 3.04 billion
• CAGR (2024 - 2030): 10.95%

Key Companies & Market Share Insights

Some prominent U.S. cell culture media market companies include Sartorius AG; Danaher Corporation Thermo Fisher Scientific, Inc.; Merck KGaA; Lonza; Cell Biologics, Inc.; and PromoCell GmbH. Key market companies such as Thermo Fisher Scientific, Inc. and Danaher Corporation have dedicated stem cell culture media portfolios, which are expected to drive market growth.

With the expansion of biosimilars and biologics market, key biopharmaceutical companies are adopting robust cell culture technologies to meet the increasing demand, thereby driving the market growth. For instance, in June 2022, FUJIFILM Corporation invested USD 1.6 billion to expand and improve the manufacturing services of cell culture in Texas. 

Key Players

• Sartorius AG
• Danaher
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• FUJIFILM Corporation
• Lonza
• BD
• STEMCELL Technologies
• Cell Biologics, Inc.
• PromoCell GmbH

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. cell culture media market is on a strong growth trajectory, fueled by advancements in cell and gene therapy, expanding biopharmaceutical production, and increasing demand from the pharmaceutical and biotechnology sectors. The supportive regulatory environment and established R&D infrastructure play a crucial role in sustaining market leadership. With rising preferences for serum-free and liquid media, the industry is leaning towards more refined, reproducible, and scalable solutions. As clinical trials for complex diseases accelerate and biosimilar development intensifies, the demand for high-quality, specialized media is expected to grow, positioning the U.S. as a critical hub for innovation and production in the global market.